Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Q3 results

    - PMLiVE

    Merck KGaA given FDA Fast Track designation for generalised myasthenia gravis drug

    Cladribine capsules could become the first ever oral treatment for gMG

    - PMLiVE

    Lilly and MeiraGTx partner in $475m ophthalmology deal

    The companies will develop and commercialise therapies for genetic conditions

    - PMLiVE

    Johnson & Jonson secures FDA approval for multiple myeloma treatment

    Support for first and only high-risk smouldering multiple myeloma treatment came from positive phase 3 trial results

    - PMLiVE

    Lilly announces agreement with US government to lower patient costs

    The agreement will make insulin and obesity treatments more affordable through federal programmes and direct-to-patient channels

    - PMLiVE

    Lilly announces plan for new $3bn facility to boost manufacturing in Europe

    The facility will be built in the Netherlands and will increase capacity for the company's oral medicines portfolio

    - PMLiVE

    GSK’s Blenrep approved by FDA for multiple myeloma

    Approval supported by positive results from phase 3 trial

    - PMLiVE

    Lilly to invest $1.2bn in Puerto Rico manufacturing site

    The investment will strengthen Lilly’s US manufacturing network

    - PMLiVE

    Lilly and WHO Foundation partner to support global dementia action plan

    The partnership will provide financial support and strengthen early detection and intervention efforts

    - PMLiVE

    Lilly’s Omvoh shows improved outcomes in ulcerative colitis

    The phase 3 trial results demonstrated improved symptomatic, clinical and quality-of-life measures

    - PMLiVE

    MHRA and FDA expand collaboration on AI and medtech regulation

    National Commission on the Regulation of AI in Healthcare brings together UK and US experts

    - PMLiVE

    Lilly appoints former US FDA director Peter Marks to lead infectious disease division

    Marks joins the drugmaker after resigning from the FDA in March

    - PMLiVE

    Roche’s small cell lung cancer therapy approved by FDA

    This is the first and only approved combination therapy for extensive-stage small cell lung cancer

    2025 T40 open for submissions
    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links